Table 1.

Effect of uPAR mAb and gemcitabine on retroperitoneal tumor invasion and liver metastasis

ControlGemcitabineuPAR mAbuPAR mAb + gemcitabine
Retroperitoneal invasion13 of 13 (100%)8 of 12 (67%) *0 of 11 (0%) 0 of 13 (0%)
Liver metastasis8 of 13 (62%)1 of 12 (8%) *1 of 11 (9%) *1 of 13 (8%) *
  • * P < 0.05 versus control.

  • P < 0.0001 versus control.